LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Immunocore Holdings PLC ADR

Slēgts

30.21 4.35

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

29.37

Max

30.49

Galvenie mērījumi

By Trading Economics

Ienākumi

29M

5M

Pārdošana

9.8M

94M

EPS

-0.49

Peļņas marža

5.35

Darbinieki

493

EBITDA

13M

-3.6M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+137.05% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 7. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-19M

1.5B

Iepriekšējā atvēršanas cena

25.86

Iepriekšējā slēgšanas cena

30.21

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 16. maijs 19:39 UTC

Galvenie tirgus virzītāji

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

2025. g. 16. maijs 23:18 UTC

Top Ziņas

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

2025. g. 16. maijs 22:30 UTC

Top Ziņas

U.S. Loses Last Triple-A Credit Rating -- Update

2025. g. 16. maijs 21:56 UTC

Tirgus saruna

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

2025. g. 16. maijs 21:56 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 16. maijs 21:54 UTC

Top Ziņas

U.S. Loses Last Triple-A Credit Rating -- WSJ

2025. g. 16. maijs 21:22 UTC

Tirgus saruna

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

2025. g. 16. maijs 21:17 UTC

Tirgus saruna

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

2025. g. 16. maijs 21:17 UTC

Top Ziņas

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

2025. g. 16. maijs 21:05 UTC

Tirgus saruna

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

2025. g. 16. maijs 20:55 UTC

Iegādes, apvienošanās, pārņemšana

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025. g. 16. maijs 20:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2025. g. 16. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 16. maijs 20:37 UTC

Top Ziņas

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

2025. g. 16. maijs 20:33 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

2025. g. 16. maijs 20:30 UTC

Iegādes, apvienošanās, pārņemšana

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

2025. g. 16. maijs 20:18 UTC

Top Ziņas

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

2025. g. 16. maijs 20:16 UTC

Top Ziņas

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

2025. g. 16. maijs 20:15 UTC

Peļņas

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

2025. g. 16. maijs 20:11 UTC

Iegādes, apvienošanās, pārņemšana

Henry Schein: William K. Daniel Joins Board

2025. g. 16. maijs 20:10 UTC

Iegādes, apvienošanās, pārņemšana

Henry Schein: Strategic Investment by KKR Completed

2025. g. 16. maijs 20:05 UTC

Iegādes, apvienošanās, pārņemšana

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025. g. 16. maijs 19:38 UTC

Tirgus saruna

Oil Futures Post Second Straight Weekly Gain -- Market Talk

2025. g. 16. maijs 19:07 UTC

Tirgus saruna

U.S. Natural Gas Futures End Week Lower -- Market Talk

2025. g. 16. maijs 18:51 UTC

Top Ziņas

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

2025. g. 16. maijs 18:41 UTC

Iegādes, apvienošanās, pārņemšana

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

2025. g. 16. maijs 18:37 UTC

Tirgus saruna

Gold Futures End Week on Negative Note -- Market Talk

2025. g. 16. maijs 18:35 UTC

Top Ziņas

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

2025. g. 16. maijs 18:32 UTC

Top Ziņas

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

2025. g. 16. maijs 18:28 UTC

Tirgus saruna

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

137.05% augšup

Prognoze 12 mēnešiem

Vidējais 65.64 USD  137.05%

Augstākais 100 USD

Zemākais 33 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

11 ratings

9

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.